COMMENT Price is key for wider market adoption of Amgen’s Amjevita Wegovy: the latest weight loss fad PROTAC development gains momentum, but clinical performance is poor FDA head Califf on tighter accelerated approvals and lower drug prices REGULATORY 4D Molecular’s Fabry gene therapy program on FDA clinical hold The company paused the enrolment of patients on two of its trials for 4D-310 last month following a ‘significant’ adverse event. insight Europe reports the highest prevalence of chronic cough comment Could vaccine hesitancy impact hearing disorders? Price is key for wider market adoption of Amgen’s Amjevita Wegovy: the latest weight loss fad PROTAC development gains momentum, but clinical performance is poor FDA head Califf on tighter accelerated approvals and lower drug prices 02/20/2023 13:54:38
Price is key for wider market adoption of Amgen’s Amjevita
Wegovy: the latest weight loss fad
PROTAC development gains momentum, but clinical performance is poor
FDA head Califf on tighter accelerated approvals and lower drug prices